Macquarie upgrades Alkem stock to Buy with INR 6,000 target

Published on 10/14/2026 at 07:07 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Macquarie set an INR 6,000 target on October 7, 2026 and upgraded Alkem. Alkem stock posted 11.00 percent first-quarter revenue growth.

Analyst target and first-quarter growth

Macquarie upgraded Alkem to Buy on October 7, 2026 with an INR 6,000 target.
First-quarter revenue rose 11.00 percent year over year to INR 37.4 billion.
Alkem traded at INR 5,220.45 on the BSE on October 14, 2026 at 10:18 a.m. IST.
Motilal Oswal retained a Neutral rating with an INR 5,770 target after the first-quarter report.

Alkem, INE540L01014, Illustration mit AI erstellt.

Macquarie upgraded Alkem Laboratories (ISIN INE540L01014) to Buy on October 7, 2026 and set a 12-month price target of INR 6,000, according to Investing.com. The analyst action gives the pharmaceutical stock a clear valuation reference after its first-quarter results.

First-quarter revenue reaches INR 37.4 billion

Alkem reported revenue growth of 11.00 percent year over year to INR 37.4 billion in the first quarter of fiscal 2027, while adjusted profit after tax declined 20.40 percent year over year to INR 5.20 billion, according to DSIJ. Earnings before interest, taxes, depreciation and amortization increased 3.70 percent to INR 7.66 billion, but the profit decline shows that sales growth did not translate evenly into earnings.

Three dated milestones shape the picture

On May 28, 2026, Alkem reported fiscal 2026 revenue growth of 13.50 percent, while adjusted profit after tax increased 17.80 percent, according to DSIJ. On August 14, 2026, the company reported first-quarter revenue of INR 37.4 billion, followed by Macquarie's October 7, 2026 upgrade and INR 6,000 target.

What does the target imply?

Alkem traded at INR 5,220.45 on the BSE on October 14, 2026 at 10:18 a.m. IST, with a market capitalization of INR 623.3 billion. The INR 6,000 target lies 14.93 percent above that quoted price, using the target and the BSE value as the same-currency reference points.

Investing.com lists 20 analysts, including 14 Buy ratings, four Holds and two Sells, with an average 12-month target of INR 6,002.55. Separately, Motilal Oswal retained a Neutral rating and set an INR 5,770 target after the first-quarter report, according to DSIJ.

Reporting dates and valuation

The August 14, 2026 first-quarter release is the latest dated results event identified for Alkem, while the October 7, 2026 Macquarie upgrade supplies the latest analyst milestone. The contrast between Macquarie's Buy view and Motilal Oswal's Neutral stance places the 11.00 percent revenue increase alongside a 20.40 percent adjusted-profit decline.